Archive for category: BioScience Managers

Research to investigate potential antimicrobial candidates against biofilms Brighton, United Kingdom – 17 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces it has signed a three-year research collaboration agreement with Aston University. The […]

Valencia, Calif., USA, and Melbourne, Australia, 28 June 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that it has entered into an agreement to acquire a manufacturing facility to support the planned U.S. launch of the RECELL® Autologous Cell Harvesting Device in the treatment of burns. The facility is currently operated a […]

“These case studies indicate that AB-SA01 may be safely administered intravenously in the critically ill and may have a role to play in the management of severe staphylococcal sepsis, for patients with resistant and life-threatening infections” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for […]

Destiny Pharma has a Scientific Advisory Board (SAB) of key opinion leaders in relevant fields to help guide and inform the future clinical development of the XF platform.  Our SAB includes the following members: David Roblin MD FRCP FFPM FMedSci (SAB Chairman) Professor David Roblin is President of Research and Development at Summit Therapeutics. David […]

Announced positive topline results for the initial seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program and presented detailed results for the first patient at a medical conference  Signed collaborative agreements with the U.S. Department of Veterans Affairs and the Westmead Hospital in Sydney  Completed two financings for combined gross proceeds of […]